Safety and proof of biological activity support clinical development of AT-001 for diabetic cardiomyopathy: a phase 1/2 study

25 May 2019 (08:30 - 17:30)

Organised by:

About the speaker

Doctor Riccardo Perfetti

New York (United States of America)

14 More presentations in this session

Presentation thumbnail

STADE-HF: A Titration based on sST2 is safe but failed to decrease readmissions in patients admitted for acute heart failure.

Mr J. Nicoleau (Montpellier, FR)

Presentation thumbnail

Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre

Miss S. Lyu (Beijing, CN)

Presentation thumbnail

Interplay of stress regulatory transcription factors in human cardiac valvular disorders leading to heart failure and cross talk of NFAtc3 nuclear localization invitro.

Professor I. Murtaza (Islamabad, PK)

Presentation thumbnail

Who is taking care of decompensations of patients after a de novo AHF episode? An outlook on the natural history through the NOVICA cohort

Doctor O. Miro (Barcelona, ES)

Presentation thumbnail

Analysis on how the emergency physician decision of hospitalization or discharge home patients with acute heart failure matches with the risk categories stratified by the MEESSI scale

Doctor O. Miro (Barcelona, ES)

Access the full session

Session thumbnail

Clinical Forum - Sat.25 May 08:30 - Tues. 28 May at 12:30

The Event

Heart Failure 2019

25 May 2019 08:30 CET

You may be interested in

Congress Presentation

Comorbidity burden assessed by the Charlson comorbidity index and its influence on prognosis of patients admitted due to heart failure

Congress Session

Chronic kidney disease and heart failure

Congress Presentation

Spectrum of non-cardiac comorbidities

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources